|
|
News Breaks | | | | December 21, 2012 | | 09:03 EDT |  | OREX | Blue Chip says Orexigen accelerating patient enrollment for The Light Study
Blue Chip Patient Recruitment, a division of Blue Chip Marketing Worldwide, said it has partnered with Orexigen Therapeutics to accelerate patient enrollment of The Light Study, Orexigen’s cardiovascular outcomes trial evaluating Contrave, an investigational medication being evaluated for the treatment of obesity. Approximately 9,000 patients will be randomized in the study within the next few weeks, nearly 14 months ahead of original forecasts, Blue Chip said. | |
|
News For OREX From The Last 14 Days Check below for free stories on OREX the last two weeks. |
|
|
| May 8, 2013 | | 16:11 EDT |  | OREX | Orexigen reports Q1 EPS (21c), consensus (34c)
Reports Q1 revenue $857,000, consensus $890,000. | | | May 6, 2013 | | 10:00 EDT |  | OREX | Orexigen management to meet with JPMorgan
 Subscribe for More Information | |
|
|
|
|
|
|
